Lanum Tablet contains Calcium Acetate 667 mg as its active ingredient and is primarily indicated for the management of hyperphosphatemia in patients with chronic kidney disease (CKD) undergoing dialysis. By binding dietary phosphate in the gastrointestinal tract, Lanum Tablet reduces phosphate absorption, thereby helping to maintain serum phosphate levels within the normal range. This action is critical in preventing complications such as secondary hyperparathyroidism, vascular calcification, and bone disorders commonly associated with elevated phosphate levels in CKD patients. The tablet should be administered orally with meals to maximize phosphate binding efficacy. Dosage adjustments should be based on serum phosphate levels and individual patient response, under the supervision of a healthcare professional. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and constipation. Lanum Tablet should be used cautiously in patients with hypercalcemia or those receiving calcium supplements to avoid hypercalcemia-related complications. It is contraindicated in patients with known hypersensitivity to calcium acetate or any tablet components. Regular monitoring of serum calcium, phosphate, and parathyroid hormone levels is recommended during therapy to ensure optimal therapeutic outcomes and minimize potential risks. Lanum Tablet is a valuable phosphate binder in the comprehensive management of mineral and bone disorder in CKD.